Date post: | 28-Dec-2015 |
Category: |
Documents |
Upload: | eustacia-parker |
View: | 213 times |
Download: | 0 times |
NYU Medical Grand Rounds Clinical Vignette
Joseph Shin MD, PGY-2
March 31, 2010
UNITED STATES
DEPARTMENT OF VETERANS
AFFAIRS
47 year-old man with chronic hepatitis C infection who is referred for further
evaluation and treatment of hepatitis C.
Chief Complaint
UNITED STATES
DEPARTMENT OF VETERANS
AFFAIRS
History of Present Illness
UNITED STATES
DEPARTMENT OF VETERANS
AFFAIRS
• The patient was in his usual state of health until approximately 6 months ago when he presented to his physician in Nashville with fatigue, insomnia, memory impairment and 25 lb weight loss.
• Routine laboratory screening eventually led to the diagnosis of hepatitis C.
Additional History
UNITED STATES
DEPARTMENT OF VETERANS
AFFAIRS
Past Medical History• Diabetes• Depression
Past Surgical History• None
Family History• Diabetes• Coronary artery disease
Social History• Egyptian-born • Immigrated in 2006• Current smoker
• 5-10 cigarettes daily• 10 pack-years
• Occasional alcohol use• Denies IV drug abuse• No tattoos
Outpatient Medications
UNITED STATES
DEPARTMENT OF VETERANS
AFFAIRS
• Glyburide 5mg po daily
• Sitagliptin 100mg po daily
• Nadolol 20mg po daily
• Multivitamin daily
• Allergies: Penicillin (rash)
Physical Examination
UNITED STATES
DEPARTMENT OF VETERANS
AFFAIRS
General: Well-appearing, obese man in no acute distress
Vitals: T 99.0, BP 110/68, HR 73, RR 18, BMI 30O2 saturation: 99% on room air
Abdomen: Soft, non-tender, mildly distended
The remainder of the physical exam was normal.No stigmata of chronic liver disease was noted.
Laboratory Results
UNITED STATES
DEPARTMENT OF VETERANS
AFFAIRS
• CBC: • WBC 3.2• Hemoglobin 13.9 g/dL, Hematocrit 44.2%• Platelets 53,000
• Basic Metabolic Panel: Within normal limits
• Hepatic Panel: • AST 55 U/L, ALT 46 U/L• Alkaline Phosphatase 102 U/L• Total Bilirubin 1.5 mg/dL • Total protein 6.9 g/dL, Albumin 3.0 g/dL
• INR: 1.2
Laboratory Results
UNITED STATES
DEPARTMENT OF VETERANS
AFFAIRS
• Hepatitis A IgM: Negative• Hepatitis A IgG: Reactive
• Hepatitis B serologies: Negative
• Hepatitis C
• Hepatitis C Ab: Reactive• Hepatitis C RNA PCR: 57,100 IU/mL• Genotype: Type 4
• Alpha-fetoprotein:
•13.6 ng/mL (normal range 0-20ng/mL)
Working Diagnoses
UNITED STATES
DEPARTMENT OF VETERANS
AFFAIRS
• Chronic Hepatitis C Infection• Thrombocytopenia
UNITED STATES
DEPARTMENT OF VETERANS
AFFAIRS
Further work-up
• Imaging studies of the abdomen were obtained, including MRI with contrast, which demonstrated:
• Liver cirrhosis• Portal hypertension • Splenomegaly, splenic varices, splenorenal shunt• Gastroesophageal varices• Iron deposition
• Esophago-gastro-duodenoscopy was performed as a part of staging, and demonstrated large esophageal and gastric varices with portal gastropathy.
Pathology
UNITED STATES
DEPARTMENT OF VETERANS
AFFAIRS
Liver Biopsy:
• Cirrhosis with mild chronic hepatitis• 2+ iron deposition in hepatocytes• Mild steatosis
Batts-Ludwig Grading Classification System:• Portal/Periportal activity: 2 of 4 (mild piecemeal necrosis)• Lobular activity: 2 of 4 (mild lobular inflammation)• Stage: 4 of 4 (cirrhosis)
• Hereditary Hemachromatosis DNA: negative for allele
UNITED STATES
DEPARTMENT OF VETERANS
AFFAIRS
Treatment Course
• Nadolol was continued for primary esophageal variceal hemorrhage prophylaxis.
• Citalopram was initiated for the treatment of depression.
• Immunizations for hepatitis B, seasonal influenza and pneumococcus were administered.
UNITED STATES
DEPARTMENT OF VETERANS
AFFAIRS
Treatment Course
• Treatment with recombinant human IL-11 (rHuIL-11) was initiated to improve thrombocytopenia prior to treatment with pegylated interferon and ribavirin.
• rHuIL-11 is a thrombopoietic growth factor that stimulates platelet production independent of the thrombopoietin receptor.
UNITED STATES
DEPARTMENT OF VETERANS
AFFAIRS
Treatment Course
• After week 4 of rHuIL-11 therapy, the patient developed dyspnea and lower extremity edema.
• A chest x-ray was performed and was normal.
• Spironolactone was started with resolution of the patient’s symptoms.
• After week 8, the patient remained thrombocytopenic, with platelet counts < 60,000.
• rHuIL-11 discontinued and patient was referred to NYU for further evaluation.
UNITED STATES
DEPARTMENT OF VETERANS
AFFAIRS
Treatment Course
• The patient was referred for screening and was enrolled in the ENABLE trial of Eltrombopag.
• Eltrombopag is a non-peptide thrombopoietin (TPO) mimetic that binds and activates the TPO receptor to stimulate increased platelet production.
• During the study, the patient’s platelet values increased from 51,000 to 136,000/mL.
• Treatment with peg-interferon and ribavirin was initiated for treatment of chronic hepatitis C.
Platelet Response on Eltrombopag and peg-IFN/ribavirin
0
20
40
60
80
100
120
140
160
180
200
1/12
/2010
1/19
/2010
1/26
/2010
2/2/
2010
2/9/
2010
2/16
/2010
2/23
/2010
3/2/
2010
3/9/
2010
3/17
/2010
3/23
/2010
Date
Pla
tele
t co
un
ts (
tho
usa
nd
s/m
L)
UNITED STATES
DEPARTMENT OF VETERANS
AFFAIRS
Eltrombopag 30mg Eltrombopag 60mg
Peg-IFN & Ribavirin
UNITED STATES
DEPARTMENT OF VETERANS
AFFAIRS
Final Diagnoses
• Thrombocytopenia• Improved on Eltrombopag
• Chronic Hepatitis C Infection• Currently on peg-interferon/ribavirin
• Cirrhosis• Portal hypertension
•Non-bleeding varices •Splenomegaly
UNITED STATES
DEPARTMENT OF VETERANS
AFFAIRS
http://clinicalcorrelations.org
Clinical CorrelationsThe NYU Internal Medicine Blog
A Daily Dose of Medicine